Product Name: Flt3 (839-845) pY842
Product Number: PE-04AZN00
| Size: | 200 µg | Price: | 35.00 | |
| $US |
Peptide Name: Flt3 (839-845) pY842
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases and for epitope mapping of phosphosite-specific antibodies. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. Y842 phosphorylation is predicted to be stimulatory for phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: DSN-pY-VVR
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases and for epitope mapping of phosphosite-specific antibodies. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. Y842 phosphorylation is predicted to be stimulatory for phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: DSN-pY-VVR
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 930.88 Da
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Storage Stability: stable
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Storage Stability: stable
Scientific Background: Flt3 (FLK2) is a protein-tyrosine kinase of the TK group and PDGFR family. It is involved in cell proliferation, differentiation and survival through the binding of its ligand, Flt3LG. Autophosphorylation of Y591 increases phosphotransferase activity. Autophosphorylation of Y599 increases phosphotransferase activity and induces interaction with SHP2 and Src. Flt3 will induce phosphorylation of Shc1 and Akt1 leading to a change in the downstream regulator mTOR. It can activate the Ras signalling pathway and lead to phosphorylation of downstream kinases such as MAPK1/ERK2 and MAPK3/ERK1. Mutations causing constitutive activity promote cell proliferation and resistance to apoptosis. Defects have been associated with acute myelogenous leukemiaFlt3 is a known oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. Flt3 is linked with Acute Myeloid Leukemia (AML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndromes (MSD), Acute Promyelocytic Leukemia, Myeloid Sarcoma, Chronic Myeloproliferative Disease (CMPD), Acute Biphenotypic Leukemia (BAL), Precursor T-Cell Acute Lymphoblastic Leukemia, Leukemia, Acute Lymphoblastic 3 (B-ALL), Acute Myeloblastic Leukemia with Maturation, Minimally Differentiated Acute Myeloblastic Leukemia is a subtype of AML, and Gastrointestinal Stromal tumour (GANT). STAT5A activation involves Y589 and Y591 phosphorylation. A Y599F mutation can interrupt Flt3 complex formation with PTPN11/SHP2.
© Kinexus Bioinformatics Corporation 2017